A review in Genes & Diseases says the genetic makeup of lung tumors and their immune environment helps explain why immunotherapy works for some patients with advanced non-small cell lung cancer but offers limited benefit to others.
Research from the First Hospital of Jilin University published this month in Genes & Diseases highlights the urgency of improving treatment selection for NSCLC.
The review, led by Chunyan Liu and colleagues, argues that PD-L1 testing — the current gatekeeper for checkpoint inhibitor therapy — captures only a sliver of the biological story.
Tumors with identical PD-L1 scores can behave radically differently depending on the company they keep: the constellation of driver mutations and the immune neighborhood they build around themselves. The authors urge clinicians to treat genetic sequencing and immune profiling as a paired decision tool, not sequential afterthoughts.
The review states that measuring PD-L1 provides useful information, but a broader assessment can reveal important differences hidden behind a single biomarker result, emphasizing that genetic context rewrites what a PD-L1 number actually means for a given patient.
Not all oncogenic drivers are created equal when the immune system is unleashed. The Jilin team synthesizes evidence showing that KRAS mutations, especially when paired with TP53 loss, tend to correlate with stronger responses to PD-1/PD-L1 blockade.
Flip the script to EGFR mutations or ALK rearrangements — common in Asian patients and never-smokers — and the same drugs often falter, with objective response rates hovering around 10 to 12 percent in monotherapy studies cited by the AME analysis.
Then there are the spoilers. STK11 and KEAP1 alterations, found in up to a third and a fifth of NSCLC cases respectively, can sculpt a “cold” tumor microenvironment that resists immune attack even when PD-L1 looks favorable.
The AME-published study by van de Haar and colleagues underscored this interplay: patients harboring STK11, KEAP1, or EGFR alterations who did respond to immunotherapy consistently carried a high tumor mutational burden (TMB ≥10 mutations/Mb). That finding birthed a composite rule — low TMB plus one of those three alterations — that flagged likely non-responders with far greater specificity than any single marker alone.
The review doesn’t stop at diagnosis; it surveys strategies to remodel the battlefield. Blocking the CD73/adenosine pathway could lift metabolic suppression of T cells. Activating STING signaling might reignite innate immune sensing. Targeting DNA damage repair pathways offers another lever.
But the authors are careful: combining immunotherapy with targeted agents or chemotherapy carries real toxicity risks — liver injury and pneumonitis chief among them — that must be weighed against mutation subtype and prior treatment history.
For patients whose disease progresses, the review proposes a return to the drawing board: repeat genomic and biomarker assessment to catch acquired resistance mechanisms and guide the next line. Several of the combination regimens discussed remain experimental, the authors note, awaiting validation in prospective trials.
The DOI for the Jilin University review is 10.1016/j.gendis.2026.102230.